Showing results (571-580 of 1,751) with videos related to
Sort By:
Pageof 176
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 14, 2010
Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodiesRong Liu, Wenguo Jiang, Ming Yang, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 14, 2010
Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicityGöran Forsberg, Niels-Jörgen Skartved, Marie Wallén-Ohman, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 14, 2010
The immunosuppressive tumor environment is the major impediment to successful therapeutic vaccination in Neu transgenic miceJoseph E Burgents, Timothy P Moran, Michelle L West, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 14, 2010
The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimuriumXiangying Zhu, Jianguo Cai, Jiajie Huang, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 14, 2010
Alternatively activated macrophage possess antitumor cytotoxicity that is induced by IL-4 and mediated by arginase-1Julia I Ellyard, Ben J C Quah, Ljubov Simson, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanomaStergios J Moschos, Cindy A Sander, Wenjun Wang, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancerDiana V Kouiavskaia, Carla A Berard, Ellen Datena, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transferSeagal Teitz-Tennenbaum, Qiao Li, Mary A Davis, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell functionCourtney Crane, Amith Panner, Russell O Pieper, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
The efficacy of an IL-1alpha vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reductionTobias Weiss, Mario Vitacolonna, Margot ZöllerPageof 176